Skip to content

ABVC BioPharma, Inc.: 10-Q filed 2020-08-14

What ABVC BioPharma, Inc. reported in its quarterly report filed 2020-08-14 (fiscal Q2 2020): 42 published measures, 121 facts as tagged in accession 0001213900-20-022086.

This filing

Form
10-Q (quarterly report)
Filed
2020-08-14
Fiscal period
fiscal Q2 2020
Accession
0001213900-20-022086 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All ABVC BioPharma, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2020-06-306,432,361USD
At 2019-12-316,927,811USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2020-06-307,876,386USD
At 2019-12-317,052,628USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2020-06-30-1,073,688USD
At 2019-12-31-150,964USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2020-06-30390,221USD
At 2019-12-31144,295USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2020-04-01 to 2020-06-30-2,184,057USD91
2020-01-01 to 2020-06-30-3,493,319USD182
2019-04-01 to 2019-06-30-614,453USD91
2019-01-01 to 2019-06-30-1,487,770USD181

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2020-01-01 to 2020-06-30-2,047,071USD182
2019-01-01 to 2019-06-30-1,396,500USD181

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2020-04-01 to 2020-06-30226,513USD91
2020-01-01 to 2020-06-30305,299USD182
2019-04-01 to 2019-06-30191,782USD91
2019-01-01 to 2019-06-30404,024USD181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2020-01-01 to 2020-06-302,255,107USD182
2019-01-01 to 2019-06-301,731,518USD181

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2020-01-01 to 2020-06-3033,300USD182
2019-01-01 to 2019-06-30-20,976USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2020-06-30-18,948,058USD
At 2019-12-31-15,851,223USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2020-04-01 to 2020-06-30-48,644USD91
2020-01-01 to 2020-06-30-89,212USD182
2019-04-01 to 2019-06-30-40,798USD91
2019-01-01 to 2019-06-30-98,343USD181

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2020-06-30507,803USD
At 2019-12-31520,930USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2020-04-01 to 2020-06-3075USD91
2020-01-01 to 2020-06-30600USD182
2019-04-01 to 2019-06-307,800USD91
2019-01-01 to 2019-06-3016,350USD181

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2020-04-01 to 2020-06-30-1,194,013USD91
2020-01-01 to 2020-06-30-2,365,390USD182
2019-04-01 to 2019-06-30-488,808USD91
2019-01-01 to 2019-06-30-1,219,374USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2020-06-301,604,854USD
At 2019-12-31878,238USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2020-04-01 to 2020-06-30140,525USD91
2020-01-01 to 2020-06-30272,042USD182
2019-04-01 to 2019-06-30132,686USD91
2019-01-01 to 2019-06-30262,572USD181

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2020-06-307,574,311USD
At 2019-12-316,814,193USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2020-06-307,812USD
At 2019-12-3123,995USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2020-04-01 to 2020-06-301,416,290USD91
2020-01-01 to 2020-06-302,662,494USD182
2019-04-01 to 2019-06-30667,238USD91
2019-01-01 to 2019-06-301,608,547USD181

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2020-04-01 to 2020-06-30222,277USD91
2020-01-01 to 2020-06-30297,104USD182
2019-04-01 to 2019-06-30178,430USD91
2019-01-01 to 2019-06-30389,173USD181

Cost of revenue

Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.

PeriodValueUnitDays
2020-04-01 to 2020-06-304,236USD91
2020-01-01 to 2020-06-308,195USD182
2019-04-01 to 2019-06-3013,352USD91
2019-01-01 to 2019-06-3014,851USD181

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

PeriodValueUnitDays
2020-04-01 to 2020-06-301,277,133USD91
2020-01-01 to 2020-06-302,430,022USD182
2019-04-01 to 2019-06-30571,669USD91
2019-01-01 to 2019-06-301,082,472USD181

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2020-04-01 to 2020-06-30139,082USD91
2020-01-01 to 2020-06-30231,872USD182
2019-04-01 to 2019-06-3087,769USD91
2019-01-01 to 2019-06-30509,725USD181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2020-06-3019,488,168shares
At 2019-12-3119,478,168shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2020-06-30406,369USD
At 2019-12-31160,443USD
At 2019-06-30556,431USD
At 2018-12-31242,781USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2020-06-3028,222,937USD
At 2019-12-3128,180,348USD

Total equity including noncontrolling interests

Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.

PeriodValueUnitDays
At 2020-06-30-1,444,025USD
At 2020-03-31-1,172,266USD
At 2019-12-31-124,817USD
At 2019-06-30-3,141,428USD
At 2019-03-31-5,526,346USD
At 2018-12-31-5,340,386USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2020-06-30383,094USD
At 2019-12-31524,445USD

Long-term debt

Long-term borrowings under this concept, which can include the current portion depending on presentation. It is not total liabilities and may exclude leases and other obligations.

PeriodValueUnitDays
At 2020-06-30124,400USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2020-06-303,776,215USD
At 2019-12-313,762,224USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2020-06-303,268,412USD
At 2019-12-313,241,294USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2020-04-01 to 2020-06-30-2,232,701USD91
2020-01-01 to 2020-06-30-3,582,531USD182
2019-04-01 to 2019-06-30-655,251USD91
2019-01-01 to 2019-06-30-1,586,113USD181

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2020-04-01 to 2020-06-30-2,184,057USD91
2020-01-01 to 2020-03-31-1,309,262USD91
2019-04-01 to 2019-06-30-614,453USD91
2019-01-01 to 2019-03-31-873,317USD90

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2020-04-01 to 2020-06-30-1,859,865USD91
2020-01-01 to 2020-06-30-3,113,854USD182
2019-04-01 to 2019-06-30-496,515USD91
2019-01-01 to 2019-06-30-1,374,972USD181

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2020-04-01 to 2020-06-3010,425USD91
2020-01-01 to 2020-06-3021,599USD182
2019-04-01 to 2019-06-3015,691USD91
2019-01-01 to 2019-06-3029,631USD181

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2020-04-01 to 2020-06-30170,179USD91
2020-01-01 to 2020-06-30176,501USD182
2019-04-01 to 2019-06-302,398USD91
2019-01-01 to 2019-06-301,898USD181

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2020-04-01 to 2020-06-30-1,038,688USD91
2020-01-01 to 2020-06-30-1,217,141USD182
2019-04-01 to 2019-06-30-166,443USD91
2019-01-01 to 2019-06-30-366,739USD181

Deferred income tax expense or benefit

The deferred portion of income tax expense or benefit, arising from timing differences. It is not tax paid in the period.

PeriodValueUnitDays
2020-01-01 to 2020-06-30-92,062USD182
2019-01-01 to 2019-06-30-101,193USD181

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2020-01-01 to 2020-06-3059,812USD182
2019-01-01 to 2019-06-302,050USD181

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2019-01-01 to 2019-06-30531,147USD181

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2020-01-01 to 2020-06-3039,845USD182
2019-01-01 to 2019-06-30258,963USD181

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2019-01-01 to 2019-06-30-1,043USD181

Inspect the source

Entity
ABVC BioPharma, Inc. / CIK 0001173313
Captured
2026-09-19T11:16:49.109Z
SEC response SHA-256
a42942c118304cb578665c27ca73d827a17f370dd57a31742c919c9b41b25c34

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001173313.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))